Cancer Letters
Volume 294, Issue 1 , Pages 1-12 , 1 August 2010

Vanadium in the detection, prevention and treatment of cancer: The in vivo evidence

  • Anupam Bishayee

      Affiliations

    • Department of Pharmaceutical Sciences, Northeastern Ohio Universities Colleges of Medicine and Pharmacy, Rootstown, OH 44272, United States
    • Corresponding Author InformationCorresponding author. Address: Department of Pharmaceutical Sciences, Northeastern Ohio Universities Colleges of Medicine and Pharmacy, 4209 State Route 44, Rootstown, OH 44272, United States. Tel.: +1 330 325 6449; fax: +1 330 325 5936.
    • ,
  • Abhijeet Waghray

      Affiliations

    • Department of Pharmaceutical Sciences, Northeastern Ohio Universities Colleges of Medicine and Pharmacy, Rootstown, OH 44272, United States
    • ,
  • Mehool A. Patel

      Affiliations

    • Division of Hematology and Medical Oncology, Department of Internal Medicine, Northeastern Ohio Universities Colleges of Medicine and Pharmacy, Rootstown, OH 44272, United States
    • Division of Hematology and Medical Oncology, Department of Internal Medicine, Summa Health System, Akron, OH 44309, United States
    • ,
  • Malay Chatterjee

      Affiliations

    • Division of Biochemistry, Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700 032, India

Received 1 December 2009 ,Revised 22 January 2010 ,Accepted 24 January 2010.

References 

  1. Almedeida M, Filipe S, Hunianes M, Mala MF, Melo R, Severino N, et al. Vanadium haloperoxidases from brown algae of the Laminariaceae family. Phytochemistry. 2001;57:633–642
  2. Sakurai H, Katoh A, Yoshikawa Y. Chemistry and biochemistry of insulin-mimetic vanadium and zinc complexes: trial for treatment of diabetes mellitus. Bull. Chem. Soc. Jpn. 2006;79:1645–1664
  3. Mukherjee B, Patra B, Mahapatra S, Banerjee P, Tewari A, Chatterjee M. Vanadium – an element of atypical biological significance. Toxicol. Lett. 2004;150:135–143
  4. Barceloux DG. Vanadium. J. Toxicol. Clin. Toxicol. 1999;37:265–278
  5. Byrne AR, Kosta L. Vanadium in foods and in human body fluids and tissues. Sci. Total Environ. 1978;10:17–30
  6. Badmaev V, Prakash S, Majeed M. Vanadium: a review of its potential role in the fight against diabetes. J. Altern. Complement. Med. 1999;5:273–291
  7. A. Bishayee, Ph.D. Thesis, Jadavpur University, Calcutta, 1995.
  8. Degani H, Gohin M, Karlish SJD, Shechter Y. Electron paramagnetic studies and insulin like effects of vanadium in rat adipocytes. Biochemistry. 1981;20:5795–5799
  9. Sabbioni E, Marafante E. Relations between iron and vanadium metabolism: in vivo incorporation of vanadium into iron proteins of the rat. J. Toxicol. Environ. Health. 1981;8:419–429
  10. Fantus IG, Deragon G, Lai R, Tang S. Modulation of insulin action by vanadate: evidence of a role for phosphotyrosine phosphatase activity to alter cellular signaling. Mol. Cell. Biochem. 1995;153:103–112
  11. Neckay BR, Nanninga LD, Nechay PS. Vanadyl (IV) and vanadate (V) binding to selected endogenous phosphate, carboxyl and amino ligands; calculations on cellular vanadium species distribution. Arch. Biochem. Biophys. 1986;251:128–138
  12. Edel J, Sabbioni E. Retention of intratrachealy instilled and ingested tetravalent and pentavalent vanadium in rat. J. Trace Elem. Electrol. Health Dis. 1988;21:23–30
  13. Domingo JL, Gomez M, Sanchez DJ, Llobet JM, Keen CL. Toxicology of vanadium compounds in diabetic rats: the action of chelating agents on vanadium accumulation. Mol. Cell. Biochem. 1995;153:233–240
  14. Merritt K, Brown SA. Distribution of titanium and vanadium following repeated injection of high-dose salts. J. Biomed. Mater. Res. 1995;29:1175–1178
  15. Setyawati IA, Thompson KH, Yuen VG, Sun Y, Battell M, Lyster DM, et al. Kinetic analysis of uptake distribution and excretion of 48V-labeled compounds in rats. J. Appl. Physiol. 1998;84:569–575
  16. Tsiani E, Fantus IG. Vanadium compounds: biological actions and potential as pharmacological agents. Trends Endocrinol. Metab. 1997;8:51–58
  17. Nriagu JP. Vanadium in the Environment, Part 2: Health Effects. New York: John Wiley and Sons, Inc.; 1998;
  18. French RJ, Jones PJ. Role of vanadium in nutrition: metabolism, essentiality and dietary consideration. Life Sci. 1993;52:339–346
  19. Stern A, Yin X, Tsang SS, Davidson A, Moon AJ. Vanadium as a modulator of cellular regulatory cascades and oncogene expression. Biochem. Cell. Biol. 1993;71:103–112
  20. Dessoize B. Metal and metal compounds in cancer treatment. Anticancer Res. 2004;24:1529–1544
  21. Kieler J, Gromek A, Nissen NI. Studies on the antineoplastic effect of vanadium salts. Acta Chir. Scand. 1965;343:154–164
  22. Evangelou AM. Vanadium in cancer treatment. Crit. Rev. Oncol. Hematol. 2002;42:249–265
  23. Ray RS, Rana B, Swami B, Venu V, Chatterjee M. Vanadium mediated apoptosis and cell cycle arrest in MCF7 cell line. Chem.–Biol. Interact. 2006;163:239–247
  24. Klein A, Holko P, Ligeza J, Kordowiak AM. Sodium orthovanadate affects growth of some human epithelial cancer cells (A549, HTB44, DU145). Folia Biol. 2008;56:115–121
  25. Kostova I. Titanium and vanadium complexes as anticancer agents. Anticancer Agents Med. Chem. 2009;9:827–842
  26. Thompson HJ, Chasten ND, Meeker LD. Dietary vanadyl (IV) sulfate inhibits chemically-induced mammary carcinogenesis. Carcinogenesis. 1984;5:849–851
  27. Bishayee A, Oinam S, Basu M, Chatterjee M. Vanadium chemoprevention of 7,12-dimethylbenz(a)anthracene-induced rat mammary carcinogenesis: probable involvement of representative hepatic phase I and II xenobiotic metabolizing enzymes. Breast Cancer Res. Treat. 2000;63:133–145
  28. Ray RS, Roy S, Ghosh S, Kumar M, Chatterjee M. Suppression of cell proliferation, DNA protein cross-links, and induction of apoptosis by vanadium in chemical rat mammary carcinogenesis. Biochim. Biophys. Acta. 2004;1675:165–173
  29. Ray RS, Basu M, Ghosh B, Smanta K, Chatterjee M. Vanadium, a versatile biochemical effector in chemical rat mammary carcinogenesis. Nutr. Cancer. 2005;51:184–186
  30. Ray RS, Roy S, Samanta S, Maitra D, Chatterjee M. Protective role of vanadium on the early process of rat mammary carcinogenesis by influencing expression of metallothionein, GGT-positive foci and DNA fragmentation. Cell Biochem. Funct. 2005;23:447–456
  31. Abdel-Mageed A, Agrawal KC. Antisense down-regulation of metallothionein induces growth arrest and apoptosis in human breast carcinoma cells. Cancer Gene Ther. 1997;4:199–207
  32. Jin R, Chow VT, Tan PH, Dheen ST, Duan W, Bay BH. Metallothionein 2A expression is associated with cell proliferation in breast cancer. Carcinogenesis. 2002;23:81–86
  33. Ray RS, Ghosh B, Rana A, Chatterjee M. Suppression of cell proliferation induction, of apoptosis and cell cycle arrest: chemopreventive activity of vanadium in vivo and in vitro. Int. J. Cancer. 2006;120:13–23
  34. Köpf-Maier P, Wagner W, Hessse B, Köpf H. Tumor inhibition by metallocenes: activity against leukemias and detection of the systemic effect. Eur. J. Cancer. 1981;17:665–669
  35. Köpf-Maier P, Krahl D. Tumor inhibition by metallocenes: ultrastructural localization of titanium and vanadium in treated tumor cells by electron energy loss spectroscopy. Chem.–Biol. Interact. 1983;44:317–328
  36. Köpf-Maier P, Wagner W, Liss E. Cytokinetic behavior of Ehrlich ascites tumor after in vivo treatment with cis – diamminedichloroplatinum(II) and metallocene dichlorides. J. Cancer Res. Clin. Oncol. 1981;201:21–30
  37. Köpf-Maier P. Development of necroses virus, activation and giant cell formation after treatment of Ehrlich ascites tumor with metallocene dichlorides. J. Cancer Res. Clin. Oncol. 1982;103:145–164
  38. Murthy MS, Rao LN. Antitumor and toxicologic properties of the organometallic anticancer agent vanadocene dichloride. Inorg. Chim. Acta. 1988;152:117–124
  39. El-Naggar MM, El-Waseef AM, El-Halafawy KM, El-Sayed IH. Antitumor activities of vanadium(IV), manganese(IV), iron(III), cobalt(II), and copper(II) complexes of 2-methylaminopyridine. Cancer Lett. 1998;133:71–76
  40. Narla RK, Chen C-L, Dong Y, Uckun F. In vivo antitumor activity of bis(4,7-dimethyl-1,10-phenanthroline sulfatooxovanadium(IV) {METVAN [VO(SO4)(Me2-Phen)2]}. Clin. Cancer Res. 2001;7:2124–2133
  41. D’Cruz OJ, Uckun FM. Metvan: a novel oxovanadium(IV) complex with broad spectrum anticancer activity. Expert Opin. Investig. Drugs. 2002;11:1829–1836
  42. Scrivens PJ, Alaoui-Jamali MA, Giannini G, Wang T, Loignon M, Batist G, et al. Cdc25A-inhibitory properties and antineoplastic activity of bisperoxovanadium analogues. Mol. Cancer Ther. 2003;2:1053–1059
  43. Kingsnorth AN, LaMuraglia GM, Ross JS, Malt RA. Vanadate supplements and 1,2-dimethylhydrazine induced colon cancer in mice: increased thymidine incorporation without enhanced carcinogenesis. Br. J. Cancer. 1986;53:683–686
  44. Kanna PS, Mahendrakumar CB, Chatterjee M, Hemalatha P, Datta S, Chakraborty P. Vanadium inhibits placental glutathione S-transferase (GST-P) positive foci in 1,2-dimethyl hydrazine induced rat colon carcinogenesis. J. Biochem. Mol. Toxicol. 2003;17:357–365
  45. Kanna PS, Mahendrakumar CB, Chakraborty T, Hemalatha P, Banerjee P, Chatterjee M. Effect of vanadium on colonic aberrant crypt foci induced in rats by 1,2-dimethyl hydrazine. World J. Gastroenterol. 2003;9:1020–1027
  46. Kanna PS, Mahendrakumar CB, Indira BN, Srivastawa S, Kalaiselvi K, Elayaraja T, et al. Chemopreventive effects of vanadium toward 1,2-dimethylhydrazine-induced genotoxicity and preneoplastic lesions in rat colon. Environ. Mol. Mutagen. 2004;44:113–118
  47. Kanna PS, Saralaya MG, Samanta K, Chatterjee M. Vanadium inhibits DNA–protein cross-links and ameliorates surface level changes of aberrant crypt foci during 1,2-dimethylhydrazine induced rat colon carcinogenesis. Cell Biol. Toxicol. 2005;21:41–52
  48. Samanta S, Swamy V, Suresh D, Rajkumar M, Rana B, Rana A, et al. Protective effects of vanadium against DMH-induced genotoxicity and carcinogenesis in rat colon: removal of O6-methylguanine DNA adducts, p53 expression, inducible nitric oxide synthase downregulation and apoptotic induction. Mutat. Res. 2008;650:123–131
  49. Samanta S, Chatterjee M, Ghosh B, Rajkumar M, Rana A, Chatterjee M. Vanadium and 1, 25 (OH)2 vitamin D3 combination in inhibitions of 1,2-dimethylhydrazine-induced rat colon carcinogenesis. Biochim. Biophys. Acta. 2008;1780:1106–1114
  50. Bishayee A, Chatterjee M. Selective enhancement of glutathione S-transferase activity in liver and extrahepatic tissues of rat following oral administration of vanadate. Acta Physiol. Pharmacol. Bulg. 1993;19:83–89
  51. Bishayee A, Chatterjee M. Time course effects of vanadium supplement on cytosolic reduced glutathione level and glutathione S-transferase activity. Biol. Trace Elem. Res. 1995;48:275–285
  52. Bishayee A, Chatterjee M. Inhibition of altered liver cell foci and persistent nodule growth by vanadium during diethylnitrosamine-induced hepatocarcinogenesis in rats. Anticancer Res. 1995;15:455–461
  53. Bishayee A, Chatterjee M. Inhibitory effect of vanadium on rat liver carcinogenesis initiated with diethylnitrosamine and promoted by phenobarbital. Br. J. Cancer. 1995;71:1214–1220
  54. Bishayee A, Karmakar R, Mandal A, Kundu SN, Chatterjee M. Vanadium-mediated chemoprotection against chemical hepatocarcinogenesis in rats: haematological and histological characteristics. Eur. J. Cancer Prev. 1997;6:58–70
  55. Bishayee A, Banik S, Mandal A, Marimuthu P, Chatterjee M. Vanadium-mediated suppression of diethylnitrosamine-induced chromosomal aberrations in rat hepatocytes and its correlation with induction of hepatic glutathione and glutathione S-transferase. Int. J. Oncol. 1997;10:413–423
  56. Chatterjee M, Bishayee A. Vanadium – a new tool for cancer prevention. In:  Nriagu JO editors. Vanadium in the Environment. Part 2: Health Effects. New York: John Wiley and Sons, Inc.; 1998;p. 347–390
  57. Bishayee A, Roy S, Chatterjee M. Characterization of selective induction and alteration of xenobiotic biotransforming enzymes by vanadium during diethylnitrosamine-induced chemical rat liver carcinogenesis. Oncol. Res. 1999;11:41–53
  58. Chakraborty A, Selvaraj S. Differential modulation of xenobiotic metabolizing enzymes by vanadium during diethylnitrosamine-induced hepatocarcinogenesis in Sprague–Dawley rats. Neoplasma. 2000;47:81–89
  59. Chakraborty T, Chatterjee A, Rana A, Dhachinamoorthi D, Kumar AP, Chatterjee M. Carcinogen-induced early molecular events and its implication in the initiation of chemical hepatocarcinogenesis in rats: chemopreventive role of vanadium on this process. Biochim. Biophys. Acta. 2007;1772:48–59
  60. Chakraborty T, Pandey N, Chatterjee A, Ghosh B, Rana B, Chatterjee M. Molecular basis of anticlastogenic potential of vanadium in vivo during the early stages of diethylnitrosamine-induced hepatocarcinogenesis in rats. Mutat. Res. 2006;609:117–128
  61. Chakraborty T, Chatterjee A, Dhachinamoorthi D, Srivastawa S, Panayappan L, Chatterjee M. Vanadium limits the expression of proliferating cell nuclear antigen and inhibits early DNA damage during diethylnitrosamine-induced hepatocellular preneoplasia in rats. Environ. Mol. Mutagen. 2006;47:603–615
  62. Chakraborty T, Chatterjee A, Saralaya MG, Chatterjee M. Chemopreventive effect of vanadium in a rodent model of chemical hepatocarcinogenesis: reflections in oxidative DNA damage, energy-dispersive X-ray fluorescence profile and metallothionein expression. J. Biol. Inorg. Chem. 2006;11:855–866
  63. Chakraborty T, Swamy AH, Chatterjee A, Rana B, Shyamsundar A, Chatterjee M. Molecular basis of vanadium-mediated inhibition of hepatocellular preneoplasia during experimental hepatocarcinogenesis in rats. J. Cell. Biochem. 2007;101:244–258
  64. Chakraborty T, Ghosh S, Datta S, Chakraborty P, Chatterjee M. Vanadium suppresses sister-chromatid exchange and DNA–protein crosslink formation and restores antioxidant status and hepatocellular architecture during 2-acetylaminofluorene-induced experimental rat hepatocarcinogenesis. J. Exp. Ther. Oncol. 2003;3:346–362
  65. Chakraborty T, Samanta S, Ghosh B, Thirumoorthy N, Chatterjee M. Vanadium induces apoptosis and modulates the expressions of metallothionein, Ki-67 nuclear antigen, and p53 during 2-acetylaminofluorene-induced rat liver preneoplasia. J. Cell. Biochem. 2005;94:744–762
  66. Chakraborty T, Chatterjee A, Saralaya MG, Dhachinamoorthi D, Chatterjee M. Vanadium inhibits the development of 2-acetylaminofluorene-induced premalignant phenotype in a two-stage chemical rat hepatocarcinogenesis model. Life Sci. 2006;78:2839–2851
  67. Chakraborty T, Chatterjee A, Rana A, Rana B, Palanisamy A, Madhappan R, et al. Suppression of early stages of neoplastic transformation in a two-stage chemical hepatocarcinogenesis model: supplementation of vanadium, a dietary micronutrient limits, cell proliferation and inhibits the formations of 8-hydroxy-2′-deoxyguanosines and DNA strand-breaks in the liver of Sprague–Dawley rats. Nutr. Cancer. 2007;59:228–247
  68. Basak R, Chatterjee M. Combined supplementation of vanadium and 1α,25-dihydroxyvitamin D3 inhibit placental glutathione S-transferase positive foci in rat liver carcinogenesis. Life Sci. 2000;68:217–231
  69. Basak R, Basu M, Chatterjee M. Combined supplementation of vanadium and 1α,25-dihydroxyvitamin D3 inhibit diethylnitrosamine-induced rat liver carcinogenesis. Chem. –Biol. Interact. 2000;128:1–18
  70. Basak R, Saha BK, Chatterjee M. Inhibition of diethylnitrosamine-induced rat liver chromosomal aberrations and DNA-strand breaks by synergistic supplementation of vanadium and 1α,25-dihydroxyvitamin D3. Biochim. Biophys. Acta. 2000;1502:273–282
  71. Chattopadhyay MB, Kumar CBM, Kanna PS, Ray RS, Roy S, Chatterjee M. Combined supplementation of vanadium and beta-carotene suppresses placental glutathione S-transferase-positive foci and enhances antioxidant functions during the inhibition of diethylnitrosamine-induced rat liver carcinogenesis. J. Gastroenterol. Hepatol. 2004;19:683–693
  72. Chattopadhyay MB, Mukherjee S, Kulkarni I, Vijayan V, Doloi M, Kanjilal NB, et al. Proton-induced X-ray emission (PIXE) analysis and DNA-chain break study in rat hepatocarcinogenesis: a possible chemopreventive role by combined supplementation of vanadium and beta-carotene. Cancer Cell Int. 2005;5:16
  73. Djordjevic C, Wampler GL. Antitumor activity and toxicity of peroxo heteroligand vanadates(V) in relation to biochemistry of vanadium. J. Inorg. Biochem. 1985;25:51–55
  74. Sardar S, Mondal A, Chatterjee M. Protective role of vanadium in the survival of hosts during the growth of a transplantable murine lymphoma and its profound effects on the rates and patterns of biotransformation. Neoplasma. 1993;40:27–30
  75. Chakraborty A, Chatterjee M. Enhanced erythropoietin and suppression of γ-glutamyl transpeptidase (GGT) activity in murine lymphoma following administration of vanadium. Neoplasma. 1994;41:291–296
  76. Chakraborty A, Ghosh R, Roy K, Ghosh S, Chowdhury P, Chatterjee M. Vanadium: a modifier of drug-metabolizing enzyme patterns and its critical role in cellular proliferation in transplantable murine lymphoma. Oncology. 1995;52:310–314
  77. Evangelou A, Karkabounas S, Kalpouzos G, Malamas M, Liasko R, Stefanou D, et al. Comparison of the therapeutic effects of two vanadium complexes administered at low dose on benzo[a]pyrene-induced malignant tumors in rats. Cancer Lett. 1997;119:221–225
  78. Liasko R, Kabanos TA, Karkabounas S, Malamas M, Tasiopoulos AJ, Stefanou D, et al. Beneficial effects of a vanadium complex with cysteine, administered at low doses on benzo(α)pyrene-induced leiomyosarcomas in Wistar rats. Anticancer Res. 1998;18:3609–3613
  79. F Cruz T, Morgan A, Min W. In vitro and in vivo antineoplastic effects of orthovanadate. Mol. Cell. Biochem. 1995;153:161–166
  80. Jackson JK, Min W, Cruz TF, Cindric S, Arsenault L, Von Hoff DD, et al. A polymer-based drug delivery system for the antineoplastic agent bis(maltolato)oxovanadium in mice. Br. J. Cancer. 1997;75:1014–1020
  81. Rizk SL, Sky-Peck H. Comparison between concentrations of trace elements in normal and neoplastic human breast tissue. Cancer Res. 1984;44:5390–5394
  82. Iwai K, Iwata R, Kawamura M, Kimura S. Localizing efficiency of [48V])vanadyl-pheophorbide in tumor as new tumor imaging agent. Int. J. Rad. Appl. Instrum. B. 1989;16:783–789
  83. Iwai K, Kimura S, Ido T, Iwata R. Tumor uptake of [8V])vanadyl-chlorine e6 Na as a tumor-imaging agent in tumor-bearing mice. Int. J. Rad. Appl. Instrum. B. 1990;17:775–780
  84. Warburg O. On the origin of cancer cells. Science. 1956;123:309–314
  85. Mustafi D, Peng B, Foxley S, Makinen MW, Karczmar GS, Zamora M, et al. New vanadium-based magnetic resonance imaging probes: clinical potential for early detection of cancer. J. Biol. Inorg. Chem. 2009;8:1187–1197
  86. Domingo JL, Sanchez DJ, Gomez M, Llobet JM, Corbella J. Oral vanadate and Tiron in treatment of diabetes mellitus in rats: improvement of glucose homeostasis and negative side-effects. Vet. Hum. Toxicol. 1993;35:495–500
  87. Bolkent S, Bolkent S, Yanardag R, Tunali S. Protective effect of vanadyl sulfate on the pancreas of streptozotocin-induced diabetic rats. Diabetes Res. Clin. Pract. 2005;70:103–109
  88. Yanardag R, Tunali S. Vanadyl sulfate administration protects the streptozotocin-induced oxidative damage to brain tissue in rats. Mol. Cell. Biochem. 2006;286:153–159
  89. Poucheret P, Verma S, Grynpas MD, McNeill JH. Vanadium and diabetes. Mol. Cell. Biochem. 1998;188:73–80
  90. National Research Council of Canada, Effects of vanadium in the Canadian environment, Report No. 18132, NRCC, Ottawa, 1980.
  91. Hirano S, Suzuki KT. Exposure metabolism and toxicity for rare earths and related compounds. Environ. Health Perspect. 1996;104:85–95
  92. Proescher F, Seil HA, Stillians AW. A contribution to the action of vanadium with particular reference to syphilis. Am. J. Syph. 1917;1:347–405
  93. Kent NL, McCance RA. The absorption and excretion of ‘minor’ elements by man: silver, gold, lithium, boron, and vanadium. Biochem. J. 1941;35:837–844
  94. Alimonti A, Petrucci F, Krachler M, Bocca B, Caroll S. Reference values for chromium, nickel and vanadium in urine of youngsters from the urban area of Rome. J. Environ. Monit. 2000;2:351–354
  95. Somerville J, Davies B. Effect of vanadium on serum cholesterol. Am. Heart J. 1962;64:54–56
  96. Dimond EG, Caravace J, Benchimol A. Vanadium, excretion, toxicity, lipid effect in man. Am. J. Clin. Nutr. 1963;12:49–53
  97. Goldfine AB, Simonson DC, Folli F, Patti ME, Kahn CR. Metabolic effects of sodium metavanadate in humans with insulin-dependent and noninsulin-dependent diabetes mellitus in vivo and in vitro studies. J. Clin. Endocrinol. Metab. 1995;80:3311–3320
  98. Halberstam M, Cohen N, Shlimovich P, Rossetti L, Shamoon H. Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects. Diabetes. 1996;45:659–666
  99. Cohen N, Halberstam M, Shlimovich P, Chang CJ, Shamoon H, Rossetti L. Oral vanadyl sulfate improves hepatic and peripheral insulin sensitivity in patients with non-insulin-dependent diabetes mellitus. J. Clin. Invest. 1995;95:2501–2509
  100. Boden G, Chen X, Ruiz J, van Rossum GD, Turco S. Effects of vanadyl sulfate on carbohydrate and lipid metabolism in patients with non-insulin-dependent diabetes mellitus. Metabolism. 1996;45:1130–1135
  101. Fawcett JP, Farquhar SJ, Thou T, Shand BI. Oral vanadyl sulphate does not affect blood cells, viscosity or biochemistry in humans. Pharmacol. Toxicol. 1997;80:202–206
  102. Goldfine AB, Patti ME, Zuberi L, Goldstein BJ, LeBlanc R, Landaker EJ, et al. Metabolic effects of vanadyl sulfate in humans with non-insulin-dependent diabetes mellitus: in vivo and in vitro studies. Metabolism. 2000;49:400–410
  103. Cusi K, Cukier S, DeFronzo A, Torres M, Puchulu FM, Pereira Redondo JC. Vanadyl sulfate improves hepatic and muscle insulin sensitivity in type 2 diabetes. J. Clin. Endocrinol. Metab. 2001;86:1410–1417
  104. Jentjens RL, Jeukendrup AE. Effect of acute and short-term administration of vanadyl sulphate on insulin sensitivity in healthy active humans. Int. J. Sport Nutr. Exerc. Metab. 2002;12:470–479
  105. Heinemann G, Fichtl B, Vogt W. Pharmacokinetics of vanadium in humans after intravenous administration of a vanadium containing albumin solution. Br. J. Clin. Pharmacol. 2003;55:241–245
  106. Thompson KH, Orvig C. Vanadium in diabetes: 100years from phase 0 to phase I. J. Inorg. Biochem. 2006;100:1925–1935
  107. Etcheverry SB, Ferrer EG, Naso L, Rivadeneira J, Salinas V, Williams PA. Antioxidant effects of the VO(IV) hesperidin complex and its role in cancer chemoprevention. J. Biol. Inorg. Chem. 2008;13:435–447

PII: S0304-3835(10)00056-X

doi: 10.1016/j.canlet.2010.01.030

Cancer Letters
Volume 294, Issue 1 , Pages 1-12 , 1 August 2010

Article Tools